Clinical Guideline Alerts December 2023 Banner
  • Anaphylaxis
    • Society:American College of Allergy, Asthma, and Immunology (ACAAI); American Academy of Allergy, Asthma & Immunology (AAAAI)
    • Published:December 17, 2023
  • Atopic Dermatitis (Eczema)
    • Society:American College of Allergy, Asthma, and Immunology (ACAAI); American Academy of Allergy, Asthma & Immunology (AAAAI)
    • Published:December 17, 2023
FDA Drug Approvals December 2023 Banner
  • Jaypirca (Eli Lilly)
    • Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor.
  • Fabhalta (Novartis)
    • Treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).
  • Avzivi (Bio-Thera Solutions) Biosimilar to Avastin
    • Biosimilar to Avastin, multiple indications.
  • Casgevy (Vertex / CRISPR)
    • Treatment of sickle cell disease (SCD) in patients 12 years and older.
  • Lyfgenia (Bluebird Bio)
    • Treatment of sickle cell disease (SCD) in patients 12 years and older.
  • Cresemba (Astellas) Expanded Indication
    • Treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients.
  • Iwilfin (US WorldMeds)
    • To treat adult and pediatric patients with high-risk neuroblastoma who have shown at least a partial response to a previous multiagent modality therapy, which includes anti-GD2 immunotherapy.
  • Adbry (Leo Pharma)Expanded Indication
    • To include pediatric patients aged 12-17 years with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
  • Alyglo (GC Biopharma)
    • Treatment of adult patients aged 17 years and older with primary humoral immunodeficiency (PI).
  • Padcev (Astellas) New Indication¬†
    • In combination with pembrolizumab (Keytruda) to treat locally advanced or metastatic urothelial cancer.
  • Filsuvez (Chiesi)¬†
    • Treatment of partial thickness wounds in patients 6 months and older with Junctional Epidermolysis Bullosa (JEB) and Dystrophic Epidermolysis Bullosa (DEB).
  • Wainua (Ionis Pharmaceuticals)
    • Treatment of Adults with Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis.

Copyright © 2024 Guideline Central, All rights reserved.